A Pilot Pharmacologic Biomarker Study of Busulfan and Fludarabine in Hematopoietic Cell Transplant Recipients

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-011-1736-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pharmacogenetics of Intravenous and Oral Busulfan in Hematopoietic Cell Transplant Recipients

Journal of Clinical Pharmacology
Pharmacology
2011English

Medication Adherence Among Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Pilot Single-Center Study

Bone Marrow Transplantation
TransplantationHematology
2017English

Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Vaccination of Hematopoietic Cell Transplant Recipients

Bone Marrow Transplantation
TransplantationHematology
2009English

Busulfan Fludarabine vs Busulfan Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Cell Transplantation: Systematic Review and Meta-Analysis

Bone Marrow Transplantation
TransplantationHematology
2015English

Invasive Aspergillosis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Analysis

Brazilian Journal of Infectious Diseases
Infectious DiseasesMicrobiology
2008English

Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant

Therapeutic Drug Monitoring
Pharmacology
2015English

Drug Resistant CMV in Pediatric Hematopoietic Stem Cell Transplant Recipients

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Frontiers in Microbiology
Microbiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy